ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2013

Physician Experience and Patient´s Disease Activity Affect the Impact of Musculoskeletal Ultrasound on the Treatment Decision in Rheumatoid Arthritis Patients

César Sifuentes-Cantú1, Irazu Contreras-Yañez2, Marwin Gutierrez3 and Virginia Pascual-Ramos4, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 3Rheumatology, Instituto Nacional de Rehabilitación, Mexico City, Mexico, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Rheumatoid arthritis (RA), treatment and ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Imaging of Rheumatic Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

In a real clinical setting of RA outpatients, we previously showed that musculoskeletal ultrasound (MUS) added to clinical evaluation impacted the treatment decision in 20% of the clinical scenarios evaluated; the impact was greater for the trainee in rheumatology (TR) than for the senior rheumatologist (SR). The aim of the present study was to explore if the results could be generalized to a higher number of physicians.

Methods:

The population of physicians consisted of 10 SR (mean age: 46.2± 12.7 years, 3 of them with ²5 years of experience, 4 with 6-14 years and 3 ³15 years) and 12 TR (median age: 30.8±1.3 years); 94% and 16.7% of the TR and the SR, respectively, referred theoretical MUS training.

10 clinical vignettes included data abstracted from 10 RA outpatients, randomly selected from an ongoing cohort. Each vignette was shared with 6 TR and 6 SR, who were asked to give a first treatment recommendation based on Òtraditional rheumatic assessmentsÓ and in a second step, to confirm or not their previous recommendation after MUS findings were incorporated to the rheumatic assessments.

Each vignette included the following data: in the first sheet, patient socio-demographic characteristics, comorbidities, extended disease activity evaluation, previous RA treatment, comorbid conditions treatment and a space for the first treatment recommendation; in the second sheet, MUS information and a space for eventual RA specific treatment changes (Figure).

Results:

Patients were middle-aged females (41.9±7 years old) with (mean±SD) disease duration of 7.5±3.4 years. Six of them had DAS28-ESR remission.

MUS added to the clinical evaluation induced a treatment modification in 26% of the 96 clinical scenarios evaluated, with similar percentage in TR (29.2%) and SR (22.9%), (p=0.64). Within SR, the lesser experienced rheumatologist (<15 years) changed their treatment proposal after MUS finding more frequently (44%) than those with ³15 years of experience (0%, p=0.002); training in MUS did not impact treatment modifications.

MUS induced more treatment modifications in those clinical scenarios with DAS28-ESR active disease vs. remission patients 68% vs 32%, p=0.005. There was a higher (albeit not significant) percentage of disagreement in disease activity level between DAS28 and MUS in active vs. remission patients: 75% vs. 32.8%, p=0.51). Then, we identified 48 clinical scenarios (50%) with disagreement in disease activity as per DAS28 and per MUS; of them 18 (37.5%) were in DAS28-ESR remission and 30 had active disease; there were a higher percentage of treatment modifications after MUS information was incorporated to clinical data in active clinical scenarios vs. remission clinical scenarios: 43.3% vs. 11.1%, p=0.026.

Conclusion:

The impact of adding MUS to clinical evaluations in the treatment decision of RA patients is affected by physician experience and disease activity status.


Disclosure: C. Sifuentes-Cantú, None; I. Contreras-Yañez, None; M. Gutierrez, None; V. Pascual-Ramos, None.

To cite this abstract in AMA style:

Sifuentes-Cantú C, Contreras-Yañez I, Gutierrez M, Pascual-Ramos V. Physician Experience and Patient´s Disease Activity Affect the Impact of Musculoskeletal Ultrasound on the Treatment Decision in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/physician-experience-and-patients-disease-activity-affect-the-impact-of-musculoskeletal-ultrasound-on-the-treatment-decision-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/physician-experience-and-patients-disease-activity-affect-the-impact-of-musculoskeletal-ultrasound-on-the-treatment-decision-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology